Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jin, S. -M. | - |
dc.contributor.author | Park, S. W. | - |
dc.contributor.author | Yoon, K. -H. | - |
dc.contributor.author | Min, K. W. | - |
dc.contributor.author | Song, K. -H. | - |
dc.contributor.author | Park, K. S. | - |
dc.contributor.author | Park, J. -Y. | - |
dc.contributor.author | Park, I. B. | - |
dc.contributor.author | Chung, C. H. | - |
dc.contributor.author | Baik, S. H. | - |
dc.contributor.author | Choi, S. H. | - |
dc.contributor.author | Lee, H. W. | - |
dc.contributor.author | Lee, I. -K. | - |
dc.contributor.author | Kim, D. -M. | - |
dc.contributor.author | Lee, M. -K. | - |
dc.date.available | 2020-02-28T09:43:42Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2015-05 | - |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/10557 | - |
dc.description.abstract | We conducted a 24-week, multicentre, double-blind, randomized study with a 28-week extension to compare the efficacy and safety of anagliptin and sitagliptin as an add-on to metformin in patients with type 2 diabetes. Patients inadequately controlled on metformin were randomized to either anagliptin (100 mg twice daily, n = 92) or sitagliptin (100 mg once daily, n = 88). The primary endpoint was the change in glycated haemoglobin (HbA1c) from baseline to week 24. The mean changes in HbA1c were -0.85 +/- 0.70%(p < 0.0001) for anagliptin and -0.83 +/- 0.61% (p < 0.0001) for sitagliptin, with a mean difference of -0.02% (95% confidence interval of difference, -0.22 to 0.18%). In both groups, the fasting proinsulin : insulin ratio significantly decreased from baseline, with improved insulin secretion. Safety profiles were similar in each group. In conclusion, the non-inferiority of the efficacy of anagliptin to sitagliptin as an add-on therapy was established with regard to efficacy and safety. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.relation.isPartOf | DIABETES OBESITY & METABOLISM | - |
dc.subject | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | - |
dc.subject | EFFICACY | - |
dc.subject | VILDAGLIPTIN | - |
dc.subject | SAFETY | - |
dc.title | Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000352255000010 | - |
dc.identifier.doi | 10.1111/dom.12429 | - |
dc.identifier.bibliographicCitation | DIABETES OBESITY & METABOLISM, v.17, no.5, pp.511 - 515 | - |
dc.identifier.scopusid | 2-s2.0-84926149257 | - |
dc.citation.endPage | 515 | - |
dc.citation.startPage | 511 | - |
dc.citation.title | DIABETES OBESITY & METABOLISM | - |
dc.citation.volume | 17 | - |
dc.citation.number | 5 | - |
dc.contributor.affiliatedAuthor | Park, I. B. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | antidiabetic drug | - |
dc.subject.keywordAuthor | diabetes care | - |
dc.subject.keywordAuthor | DPP-IV inhibitor | - |
dc.subject.keywordAuthor | incretin therapy | - |
dc.subject.keywordPlus | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | VILDAGLIPTIN | - |
dc.subject.keywordPlus | SAFETY | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.